Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jan-Feb;27(1):87-88.
doi: 10.1016/j.pulmoe.2020.10.003. Epub 2020 Oct 21.

Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors' reply

A Cortegiani  1 , M Ippolito  2 , S Einav  3
Affiliations
Comment

Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors' reply

A Cortegiani et al. Pulmonology. 2021 Jan-Feb.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Kow C.S., Hasan S.S. Interleukin-6 blockade with tocilizumab in COVID-19: Does it live up to its hype? Pulmonology. 2020 doi: 10.1016/j.pulmoe.2020.10.004. - DOI - PMC - PubMed
    1. Cortegiani A., Ippolito M., Greco M., Granone V., Protti A., Gregoretti C. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. Pulmonology. 2020 doi: 10.1016/j.pulmoe.2020.07.003. Jul 20:S2531-0437(20)30153-7. - DOI - PMC - PubMed
    1. Cortegiani A., Ippolito M., Ingoglia G., Iozzo P., Giarratano A., Einav S. Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. J Crit Care. 2020;59:176–190. doi: 10.1016/j.jcrc.2020.06.019. - DOI - PMC - PubMed
    1. Furlow B. COVACTA trial raises questions about tocilizumab’s benefit in COVID-19. Lancet Rheumatol. 2020;2(10) e592. - PMC - PubMed

Substances